Dxcover Early Cancer Detection Platform Founder & CEO Professor Matt Baker Featured Panelist at Global EIE24 Meeting
May 13 2024 - 7:55AM
Business Wire
Dxcover generating early cancer detection
evidence in US, UK and EU clinical trials
Dxcover Limited, a clinical-stage diagnostics company pioneering
its multi-omic spectral analysis (MOSA) for early detection of
solid tumor cancers, Founder & CEO Professor Matthew J. Baker
was a featured panelist at the EIE24 ”Where Scotland’s Innovation
Meets Investment” investor event held at the University of
Edinburgh April 30-May 1 2024. EIE24 brought together some of
Scotland’s highest-growth technology companies and over 130
investors from around the world for two days of networking,
discovery, and deal-making.
As one of the Chief Executive panelists focused on disruptive
technologies with the potential to transform healthcare, Professor
Baker shared, “Dxcover was founded to enable the earliest detection
of cancer and we are thrilled to present at events like EIE, and
share our science with potential collaborators, partners and
investors.” He highlighted Dxcover's groundbreaking PANAROMIC™
platform, a multi-omic spectral analysis technology that holds
immense promise for the early detection of various cancers,
including brain, advanced adenoma, colorectal, lung and other solid
tumors. SIS Ventures Impact Investors, an EIE24 Ecosystem Partner
and investor in Dxcover, sponsored the panel.
The Dxcover PANAROMIC platform utilizes a revolutionary approach
called multi-omic spectral analysis to detect cancer in its
earliest stages. This technology goes beyond traditional methods by
analyzing inclusive signals missed by current cell-free DNA
testing. Dxcover's platform has achieved 99% specificity for
early-stage tumors and has been validated in over 3,000 patient
samples across various cancers. This versatile platform can be
adapted for high sensitivity (ruling out cancer) or high
specificity (ruling in cancer.)
Extending its global reach to advance the platform in early
cancer detection, Dxcover is scheduling partnering meetings at BIO
International June 3-6 2024 in San Diego, California. BIO
International is the largest and most comprehensive event for
biotechnology, representing the full ecosystem of biotech with over
20,000 industry leaders from across the globe. Dxcover is one of
several companies among Scottish Development International
attending BIO International 2024.
About Dxcover Limited
Dxcover’s ‘Drop. Dry. Detect.’™ method provides results in
minutes and is powered by artificial intelligence trained to detect
the signs of cancer. The company is currently advancing its test
for brain cancer through multi-center European studies to obtain
IVDR approval and conducting a major prospective study in the US
and EU for colorectal cancer and advanced adenoma early
detection.
Dxcover is a spin-out from the University of Strathclyde, based
on world-leading research and fronted by an award-winning team
dedicated to translating this technology into the clinic. Dxcover's
platform is patented in the US, EU, and China, with a global
mission to democratize cancer care. Dxcover is headquartered in
Glasgow UK and recently incorporated within the US.
For further information go to
https://www.dxcover.com/science.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240513263127/en/
Stacy Chick stacy.chick@dxcover.com